PMID- 27817216
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20220408
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 33
IP  - 2
DP  - 2017 Feb
TI  - Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in 
      a Chinese population with type 2 diabetes mellitus.
PG  - 359-369
LID - 10.1080/03007995.2016.1257978 [doi]
AB  - OBJECTIVE: To evaluate the long-term cost-effectiveness of dapagliflozin (a novel 
      sodium-glucose co-transporter-2 inhibitor) versus glimepiride (a widely used 
      sulfonylurea), when applied as monotherapy in patients with type 2 diabetes 
      mellitus (T2DM) in China. METHODS: Literature screening, meta-analysis and 
      indirect comparison were used to compare efficacy and safety between 
      dapagliflozin and glimepiride. Direct medication costs and medical expenditure on 
      treating diabetes related comorbidities were calculated based on published and 
      local sources and reported in 2015 Chinese Renminbi (RMB). A discount rate of 3% 
      was applied to both costs and health effects. The Cardiff model, an economic 
      model designed to evaluate the cost-effectiveness of comparator therapies in 
      diabetes, was used to generate outputs including macrovascular and microvascular 
      complications, diabetes-specific mortality, costs and quality-adjusted life years 
      (QALYs) over a time horizon of 40 years from the health provider perspective. 
      Univariate and probabilistic sensitivity analyses were performed to assess 
      uncertainty in the model results. RESULTS: Compared with glimepiride, patients on 
      dapagliflozin gained 1.01 QALYs, at a cost saving of RMB 49,065 in our simulated 
      cohort. This resulted in a cost saving of RMB 48,585 per QALY gained with 
      dapagliflozin. The cost-effectiveness results were robust to various sensitivity 
      analyses including probabilistic sensitivity analysis (PSA). CONCLUSIONS: 
      Compared with glimepiride, dapagliflozin as monotherapy for T2DM is a more 
      cost-effective treatment for T2DM patients on monotherapy in China. The weight 
      control has been identified as the major contributor for the higher 
      cost-effectiveness of dapagliflozin.
FAU - Shao, Hui
AU  - Shao H
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
FAU - Zhai, Suodi
AU  - Zhai S
AD  - b Department of Pharmacy , Peking University Third Hospital , Beijing , China.
FAU - Zou, Dajin
AU  - Zou D
AD  - c Department of Endocrinology , Changhai Hospital, Second Military Medical 
      University , Shanghai , China.
FAU - Mir, Mohammed Umer
AU  - Mir MU
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
FAU - Zawadzki, Nadine K
AU  - Zawadzki NK
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
FAU - Shi, Qian
AU  - Shi Q
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
FAU - Liu, Shuqian
AU  - Liu S
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
FAU - Shi, Lizheng
AU  - Shi L
AD  - a Department of Global Health Management and Policy , School of Public Health and 
      Tropical Medicine, Tulane University , New Orleans , LA , USA.
LA  - eng
PT  - Journal Article
DEP - 20161123
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - 6KY687524K (glimepiride)
SB  - IM
MH  - Benzhydryl Compounds/economics/*therapeutic use
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucosides/economics/*therapeutic use
MH  - Health Care Costs
MH  - Humans
MH  - Hypoglycemic Agents/economics/*therapeutic use
MH  - Models, Economic
MH  - Quality-Adjusted Life Years
MH  - Sulfonylurea Compounds/economics/*therapeutic use
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - dapagliflozin
OT  - glimepiride
OT  - monotherapy
OT  - type 2 diabetes mellitus
EDAT- 2016/11/08 06:00
MHDA- 2017/09/16 06:00
CRDT- 2016/11/08 06:00
PHST- 2016/11/08 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2016/11/08 06:00 [entrez]
AID - 10.1080/03007995.2016.1257978 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2017 Feb;33(2):359-369. doi: 10.1080/03007995.2016.1257978. 
      Epub 2016 Nov 23.